Views & Analysis | Perspectives on pharma industry issues

Digital

Changing Faces: Digital and supplier hires, June and July 20...

The pharma-adjacent tech and services sectors continued to attract experienced leadership talent during June and July.

Patients

Innovation can transform NHS care, but scaling is the missin...

Innovation is already improving care across the NHS, but we are not yet consistently delivering at scale for the benefit of patients

R&D

A physiotherapist assists an ALS patient

Treating mechanisms, not symptoms: ALS R&D today

The ALS clinical trial landscape is characterised by a significant number of active trials and sponsors, including MediciNova's Ph3 with MN-166.

R&D

Why storage resilience will protect the future of CAR-T

Cell and gene therapies are changing the way pharmaceutical organisations think about sample storage.

Patients

Reshaping the future of patient-centric drug development

Strategic partnerships, robust quality systems, and manufacturing know-how will support next-generation therapies with patient-centric designs.

Views & Analysis

Is Tecfidera’s patent win a pyrrhic victory for Biogen?

Shares in Biogen jumped last week after the company successfully defended its blockbuster MS drug Tecfidera from a patent challenge – but will the boost mean much when the company still fac

Views & Analysis

What HCPs think about pharma

For a long time, I have been observing how healthcare professionals (HCPs) are talking about the pharmaceutical industry – including their conversations about how the pharmaceutical industr

Views & Analysis

Q&A--Fortress-Biotech-on-breathing-new-life-into-abandoned-drugs

Q&A: Fortress Biotech’s Lindsay Rosenwald on breathing new l...

One downside of the explosion in our knowledge about potential drug targets is that many promising candidates are getting left on the backburner.

Sales & Marketing

Personalisation is the biggest lie brands keep telling

Pharma brands need to move beyond surface-level personalisation and focus on measurable impact.

Sales & Marketing

M&A trends in diagnostics and life sciences tools

The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large corporates.

Digital

Changing Faces: Digital and supplier hires, June and July 20...

The pharma-adjacent tech and services sectors continued to attract experienced leadership talent during June and July.

Digital

Australia, AI, and Autolomous

pharmaphorum spoke with Alexander Seyf, CEO of Autolomous, about the future of AI in Australian biotech.

Market Access

Europe’s new HTA reality: The JCA, one year on

Here, we examine the early realities of JCA implementation, exploring whether the system is delivering greater alignment across European markets.

Market Access

Three separate injections - blue, red, and yellow - take off against black background

Why global pharmaceutical reforms are quietly redirecting ra...

Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs